French set up expert groups on emerging technology:
This article was originally published in Clinica
Executive Summary
The French healthcare products safety agency, AFSSaPS, has set up three expert groups to ensure that it has at its fingertips the necessary responses to problems related to cutting-edge developments in healthcare techniques and materials. The first will assess applications for gene therapy clinical trials, investigate any "undesirable effects" of such investigations and give an opinion on any related questions likely to arise in biomedical research. The second, on cell therapy (excluding haematopoietic stems cells intended for haematopoietic reconstitution) will have a similar brief. The third is a working group on non-clinical aspects of healthcare products, which will review the techniques used in toxicology to define good practice requirements that may eventually be incorporated into new regulations.
You may also be interested in...
WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency
The World Health Organization is looking to finalize its guidance on the ethical criteria that should be applied to studies that involve deliberately infecting healthy individuals to speed up research.
Irish Body Sets Out Five-Year Vision Strategy For Off-Patent Sector
With a focus on drug accessibility, supply chain resilience, and a balanced approach to sustainability, Medicines for Ireland “calls to action” with its five-year plan.
Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages
The UK is not alone in experiencing drug shortages, as data from across Europe show, but its departure from the EU makes it more difficult to respond to supply chain pressures, according to new research.